MHRA approved Bafna Pharma’s Finasteride
Bafna Pharmaceuticals, an India-based pharmaceutical company, has received UK MHRA approval for the manufacturing of the drug Finasteride to treat enlarged prostate gland.
Indian Propecia
Finasteride is an antiandrogen which acts by inhibiting 5-alpha reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT). It works by blocking the body’s production of the male hormone that causes the prostate to enlarge.
Bafna Pharmaceuticals CMD Mahaveer Chand Bafna said that Bafna Pharma has been constantly upgrading its manufacturing facilities to efficiently meet the anticipated demands of the global markets.
The UK regulatory agency has approved Bafna for the manufacturing of Finasteride in strength of 5 mg. There is 1 mg of finasteride in Propecia and 5 mg in Proscar.
Related posts:
- Bafna Pharmaceuticals Amlodipine get MHRA approval The MHRA (UK Medicines and Healthcare products Regulatory Agency) has...
- Finasteride Finasteride (FINPECIA, PROPECIA) is approved for the treatment of male...

